Skip to main content
Erschienen in: Journal of Gastroenterology 10/2015

01.10.2015 | Original Article—Liver, Pancreas, and Biliary Tract

A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus

verfasst von: Satoshi Hiramine, Masaya Sugiyama, Norihiro Furusyo, Hirofumi Uto, Akio Ido, Hirohito Tsubouchi, Hisayoshi Watanabe, Yoshiyuki Ueno, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Jun Hayashi, David L. Thomas, Masashi Mizokami

Erschienen in: Journal of Gastroenterology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Genome-wide association studies have revealed several single-nucleotide polymorphisms around interleukin 28B (IL28B) that are strongly associated with hepatitis C virus (HCV) clearance. However, their predictive value is not perfect, which suggests that other genetic factors may also be involved in HCV clearance. We previously reported a wide variation in the length of a thymine–adenine (TA) dinucleotide repeat in the promoter region of IL28B and that the transcriptional activity of the promoter increased gradually in a TA repeat length-dependent manner.

Methods

We determined the length of the TA repeats of 1,060 Japanese and 201 African-American samples to investigate the relation to spontaneous HCV clearance.

Results

The distribution of the TA repeats greatly differed between the two ethnicities. The variation ranged from 10 to 18 repeats, and the most frequent allele, 12, accounted for over 80 % for Japanese. The African-American data showed a gently sloping distribution, and the allele with six repeats was detected only in the African-American sample. The TA repeats 11 or greater were correlated with spontaneous clearance. Multiple logistic regression analysis extracted the genotype of the TA repeats as an independent factor in both the Japanese [p = 0.0004, odds ratio (OR) = 13.02 95 % confidence interval (CI) = 2.59–237.0] and African-American (p = 0.027, OR = 3.70 95 % CI = 1.16–11.8) populations.

Conclusions

A long TA repeat in the promoter region of IL28B was associated with spontaneous HCV clearance. Although its efficacy may be limited in Japanese population because of its allele distribution, this novel genetic factor will be useful for predicting HCV clearance especially for the African Americans.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
3.
Zurück zum Zitat Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.PubMedCrossRef Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.PubMedCrossRef
4.
Zurück zum Zitat Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRef Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRef
5.
Zurück zum Zitat Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of PEGylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094–104.PubMedCrossRef Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of PEGylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094–104.PubMedCrossRef
6.
Zurück zum Zitat Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRef Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRef
7.
Zurück zum Zitat Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRef Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRef
8.
Zurück zum Zitat Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRef Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRef
9.
Zurück zum Zitat Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.PubMedCrossRef Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.PubMedCrossRef
10.
Zurück zum Zitat Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–98.PubMedCrossRef Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–98.PubMedCrossRef
11.
12.
Zurück zum Zitat Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173–81.PubMedCrossRef Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173–81.PubMedCrossRef
14.
Zurück zum Zitat Kishihara Y, Furusyo N, Kashiwagi K, et al. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis. 2001;184:1114–9.PubMedCrossRef Kishihara Y, Furusyo N, Kashiwagi K, et al. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis. 2001;184:1114–9.PubMedCrossRef
15.
Zurück zum Zitat Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology. 2009;50:393–9.PubMedPubMedCentralCrossRef Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology. 2009;50:393–9.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Watanabe H, Saito T, Shinzawa H, et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol. 2003;71:56–61.PubMedCrossRef Watanabe H, Saito T, Shinzawa H, et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol. 2003;71:56–61.PubMedCrossRef
17.
Zurück zum Zitat Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.PubMed Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.PubMed
18.
Zurück zum Zitat Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to PEGylated alpha interferon/ribavirin therapy in Japanese patients than other single-nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.PubMedPubMedCentralCrossRef Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to PEGylated alpha interferon/ribavirin therapy in Japanese patients than other single-nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17:292–6.PubMedCrossRef Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17:292–6.PubMedCrossRef
20.
Zurück zum Zitat Lyamichev VI, Kaiser MW, Lyamicheva NE, et al. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry. 2000;39:9523–32.PubMedCrossRef Lyamichev VI, Kaiser MW, Lyamicheva NE, et al. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry. 2000;39:9523–32.PubMedCrossRef
21.
Zurück zum Zitat Ishibashi M, Shinzawa H, Kuboki M, et al. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age-and area-related features. J Epidemiol. 1996;6:1–7.PubMedCrossRef Ishibashi M, Shinzawa H, Kuboki M, et al. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age-and area-related features. J Epidemiol. 1996;6:1–7.PubMedCrossRef
22.
Zurück zum Zitat Uto H, Hayashi K, Kusumoto K, et al. Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res. 2006;34:28–34.PubMedCrossRef Uto H, Hayashi K, Kusumoto K, et al. Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res. 2006;34:28–34.PubMedCrossRef
23.
Zurück zum Zitat Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.PubMedCrossRef Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.PubMedCrossRef
24.
Zurück zum Zitat Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105–11.PubMedCrossRef Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105–11.PubMedCrossRef
25.
Zurück zum Zitat Raijmakers MT, Jansen PL, Steegers EA, et al. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol. 2000;33:348–51.PubMedCrossRef Raijmakers MT, Jansen PL, Steegers EA, et al. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol. 2000;33:348–51.PubMedCrossRef
26.
Zurück zum Zitat Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. Hepatology. 2000;32:792–5.PubMedCrossRef Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. Hepatology. 2000;32:792–5.PubMedCrossRef
27.
Zurück zum Zitat Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95:8170–4.PubMedPubMedCentralCrossRef Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95:8170–4.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Horsfall LJ, Zeitlyn D, Tarekegn A, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011;75:236–46.PubMedCrossRef Horsfall LJ, Zeitlyn D, Tarekegn A, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011;75:236–46.PubMedCrossRef
29.
Zurück zum Zitat Lankisch TO, Schulz C, Zwingers T, et al. Gilbert’s syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 2008;17:695–701.PubMedCrossRef Lankisch TO, Schulz C, Zwingers T, et al. Gilbert’s syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 2008;17:695–701.PubMedCrossRef
30.
Zurück zum Zitat Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–33.PubMedCrossRef Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–33.PubMedCrossRef
31.
Zurück zum Zitat Tanaka Y, Nishida N, Sugiyama M, et al. lambda-Interferons and the single-nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010;40:449–60.PubMedCrossRef Tanaka Y, Nishida N, Sugiyama M, et al. lambda-Interferons and the single-nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010;40:449–60.PubMedCrossRef
Metadaten
Titel
A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus
verfasst von
Satoshi Hiramine
Masaya Sugiyama
Norihiro Furusyo
Hirofumi Uto
Akio Ido
Hirohito Tsubouchi
Hisayoshi Watanabe
Yoshiyuki Ueno
Masaaki Korenaga
Kazumoto Murata
Naohiko Masaki
Jun Hayashi
David L. Thomas
Masashi Mizokami
Publikationsdatum
01.10.2015
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 10/2015
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1056-1

Weitere Artikel der Ausgabe 10/2015

Journal of Gastroenterology 10/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.